上海信公轶禾企业管理咨询有限公司 关于 康龙化成（北京）新药技术股份有限公司 2022 年 A 股限制性股票激励计划 第二个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二四年八月 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 目 录 | 第一章 | 声 明 3 | | | --- | --- | --- | | 第二章 | 释 义 5 | | | 第三章 | 基本假设 7 | | | 第四章 | 本激励计划履行的审批程序 8 | | | 第五章 | 本激励计划第二个归属期归属条件成就情况 10 | | | | 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 | 10 | | 二、第二个归属期情况 | | 10 | | | 三、第二个归属期归属条件成就的说明 | 10 | | | 四、本次实施的激励计划与已披露的激励计划相关情况的差异 | 11 | | 第六章 | 本次限制性股票可归属的具体情况 13 | | | | 一、本次可归属的激励对象及归属数量 | 13 | | | 二、本次归属条件成就之日和第二个归属期限制性股票继续禁售的说明 | 13 | | 第七 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-060 康龙化成（北京）新药技术股份有限公司 关于作废失效 2021 年、2022 年、2023 年 A 股限制性股票激励 计划部分已授予但尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"或"康龙化 成"）于 2024 年 8 月 27 日召开第三届董事会第九次会议、第三届监事会第八次 会议，审议通过了《关于作废失效 2021 年、2022 年、2023 年 A 股限制性股票 激励计划部分已授予但尚未归属的限制性股票的议案》，现将有关事项说明如 下： 一、本次作废失效限制性股票的具体情况 根据公司《2021 年 A 股限制性股票激励计划》《2022 年 A 股限制性股票激 励计划》《2023年 A 股限制性股票激励计划》的有关规定及公司 2021年第一次 临时股东大会、2021 年第二次 A 股类别股东大会及 2021 年第二次 H 股类别股 东大会，2021 年年度股东大会、2022 年第二次 A 股类别股东大会 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-055 康龙化成（北京）新药技术股份有限公司 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"或"本公司"） 第三届董事会第九次会议于 2024 年 8 月 27 日在公司北京办公室以现场会议和 通讯相结合的方式召开，其中，楼小强先生、胡柏风先生、李家庆先生和周其林 先生以通讯方式参会。本次会议通知及会议材料于 2024 年 8 月 13 日以邮件形式 向全体董事发出。会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董 事长 Boliang Lou 博士主持，公司部分高级管理人员列席了本次会议。本次会议 的召集和召开符合《中华人民共和国公司法》等有关法律、行政法规、部门规章、 规范性文件和《康龙化成（北京）新药技术股份有限公司章程》的规定。 二、董事会会议审议情况 与会董事审议并以记名投票方式通过了以下议案： （一）审议通过《关于 2024 年半年度报告全文、报告摘要及中期业绩 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-054 康龙化成（北京）新药技术股份有限公司 特别提示： 康龙化成（北京）新药技术股份有限公司（以下简称"公司"或"本公司"） 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企业、 上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 公司于 2024 年 8 月 27 日召开第三届董事会第九次会议，审议通过了《关于 拟续聘 2024 年度境内财务及内控审计机构的议案》。公司董事会同意续聘安永华 明会计师事务所（特殊普通合伙）（以下简称"安永华明"）作为公司境内财务及 内控审计机构。本议案尚需提交公司股东大会审议。现将有关事项公告如下： 一、机构信息 （一）基本信息 安永华明，于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外 合作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。截至 2023 年末拥有合伙人 245 人，首席合伙人为毛鞍宁先生。安永华明一直以来注 重人才培养，截至 2 ...

康龙化成（北京）新药技术股份有限公司 证券代码：300759 证券简称：康龙化成 公告编号：2024-057 关于调整 2021 年、2022 年、2023 年 A 股限制性股票激励 计划相关事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于2024年8月27 日召开第三届董事会第九次会议和第三届监事会第八次会议，审议通过了《关于 调整2021年、2022年、2023年A股限制性股票激励计划相关事项的议案》，根据 公司《2021年A股限制性股票激励计划》（以下简称"2021年A股激励计划"）、 《2022年A股限制性股票激励计划》（以下简称"2022年A股激励计划"）、《2023 年A股限制性股票激励计划》（以下简称"2023年A股激励计划"）的相关规定 及公司2021年第一次临时股东大会、2021年第二次A股类别股东大会及2021年第 二次H股类别股东大会，2021年年度股东大会、2022年第二次A股类别股东大会 及2022年第二次H股类别股东大会，2022年年度股东大会、2023年第一次A ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-058 康龙化成（北京）新药技术股份有限公司 关于 2021 年 A 股限制性股票激励计划 第三个归属期归属条件成就 1、限制性股票拟归属数量：本次符合归属条件的激励对象共计 176 名，均 满足 100%归属条件，可归属的限制性股票数量为 371,460 股，占公司目前总股 本的 0.02%； 2、归属股票来源：公司向激励对象定向发行的本公司人民币 A 股普通股股 票； 但股票暂不上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 3、本次限制性股票归属条件成就之日为 2024 年 7 月 27 日； 4、根据公司 2021 年 A 股限制性股票激励计划（以下简称"本次激励计划"） 所有激励对象承诺，自每期限制性股票经董事会审议确定的归属条件成就之日起 6 个月内，不转让其所持有的当批次归属的全部限制性股票。因此公司申请本次 归属的限制性股票暂不上市，继续禁售至 2025 年 1 月 26 日。公司将延迟到禁售 期结束时向深圳证券交易所、中国证券登记结算有限责任公司深圳分 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-056 康龙化成（北京）新药技术股份有限公司 第三届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）第三届监事 会第八次会议于 2024 年 8 月 27 日以通讯方式召开，本次会议通知于 2024 年 8 月 23 日以邮件形式向全体监事发出。会议应出席监事 3 名，实际出席监事 3 名。 本次会议由监事会主席 Kexin Yang 博士主持，公司董事会秘书列席了本次会议。 本次会议的召集和召开符合《中华人民共和国公司法》等有关法律、行政法规、 部门规章、规范性文件和《康龙化成（北京）新药技术股份有限公司章程》的规 定。 二、监事会会议审议情况 1 表决结果：3 票同意，0 票反对，0 票弃权。 （二）审议通过《关于拟续聘 2024 年度境内财务及内控审计机构的议案》 公司监事会同意续聘安永华明会计师事务所（特殊普通合伙）为公司 2024 年度境内财务及内控审计机构。 具体内容详见公司于同日 ...

Financial Performance - Revenue for the first half of 2024 reached $1.2 billion, representing a 15% year-over-year growth[2] - Net profit for the first half of 2024 was $180 million, a 12% increase compared to the same period last year[2] - Revenue for the first half of 2024 was RMB 5,604.46 million, a slight decrease of 0.63% year-over-year[15] - Net profit attributable to shareholders increased by 41.64% to RMB 1,113.40 million compared to the same period last year[15] - Adjusted non-IFRS net profit attributable to shareholders decreased by 25.93% to RMB 690.27 million[22] - The company expects full-year 2024 revenue to grow by 12-15%, reaching $2.5-2.6 billion[4] - Revenue from clients using multiple business segments accounted for 71.16% of total revenue, amounting to RMB 3,987.94 million[23] - Revenue from North American clients was RMB 3,668.22 million, accounting for 65.45% of total revenue, a slight decrease of 0.20% year-over-year[24] - Revenue from European clients (including the UK) increased by 9.98% to RMB 945.58 million, accounting for 16.87% of total revenue[24] - The company served over 2,200 global clients, with over 360 new clients contributing RMB 161.24 million, or 2.88% of total revenue[23] - Overseas subsidiaries delivered revenue of RMB 736.83 million, a 3.99% increase year-over-year, accounting for 13.15% of total revenue[25] - Laboratory services revenue for the first half of 2024 was 3,371.1768 million yuan, a slight decrease of 0.27% year-over-year, with a gross margin of 44.46%, down 0.59 percentage points[27] - CMC (small molecule CDMO) services revenue for the first half of 2024 was 1,175.7473 million yuan, a decrease of 6.04% year-over-year, with a gross margin of 28.30%, down 4.16 percentage points[28] - Clinical research services revenue for the first half of 2024 was 843.2694 million yuan, an increase of 4.73% year-over-year, with a gross margin of 12.55%, down 4.43 percentage points[30] - The company's large molecule and cell & gene therapy services generated revenue of 211.21 million yuan, a year-on-year increase of 5.49%, with Q2 2024 revenue reaching 119.78 million yuan, a 31.00% increase from Q1 2024[32] - The gross margin for large molecule and gene therapy CDMO services was -31.34% in H1 2024 due to ongoing construction and operational costs[32] - Revenue for the first half of 2024 was RMB 5,604,463,354.87, a slight decrease of 0.63% compared to the same period last year[48] - Operating costs increased by 3.96% to RMB 3,733,284,838.30, while sales expenses decreased by 3.02% to RMB 122,949,469.45[48] - R&D investment increased by 14.06% to RMB 207,797,841.87, reflecting the company's commitment to innovation[48] - Net cash flow from operating activities decreased by 14.10% to RMB 1,099,735,310.22, while net cash flow from financing activities saw a significant decrease of 825.39% to RMB -4,653,026,429.44[48] - Laboratory services accounted for the largest portion of revenue at RMB 3,371,176,816.35, with a gross margin of 44.46%[49] - CMC (small molecule CDMO) services revenue decreased by 6.04% to RMB 1,175,747,332.83, with a gross margin of 28.30%[49] - Clinical research services revenue increased by 4.73% to RMB 843,269,367.02, but the gross margin decreased by 4.43% to 12.55%[49] - The company's cash and cash equivalents decreased by 414.22% to RMB -3,506,304,159.12, primarily due to increased cash outflows from financing activities[48] - The company's investment income was RMB 634,095,077.59, accounting for 51.68% of total profit, mainly from the disposal of non-current financial assets and the redemption of convertible bonds[50] - Cash and cash equivalents decreased by RMB 350.63 million, a drop of 59.44% compared to the end of the previous year[52] - Accounts receivable increased by 1.01% to RMB 89 million, representing 9.48% of total assets[52] - Inventory increased by 1.34% to RMB 1.188 billion, accounting for 5.17% of total assets[52] - Fixed assets grew by 7.63% to RMB 7.398 billion, representing 32.17% of total assets[52] - Prepayments increased by RMB 8.2274 million, a rise of 46.20%, mainly due to increased prepayments for raw material procurement[52] - Long-term prepaid expenses increased by RMB 184.6683 million, a growth of 35.48%, primarily due to new operating lease property improvements[52] - Trading financial assets decreased by RMB 260.8939 million, a drop of 41.95%, mainly due to the redemption of low-risk bank wealth management products[52] - Long-term equity investment increased by 0.46% to RMB 734.2411 million, representing 3.19% of total assets[52] - The company's investment in the UK subsidiary, Kanglong (UK), accounted for 13.78% of the company's net assets, with a net profit of RMB 35.0722 million for the reporting period[54] - Total investment during the reporting period was RMB 2.7588 billion, an increase of 4.93% compared to the same period last year[57] - The company's financial assets measured at fair value had a total initial investment cost of 2,128,576,048.84 yuan, with a cumulative investment income of 573,579,951.29 yuan[58] - The company's other financial assets had an initial investment cost of 1,861,000,000.00 yuan, with a cumulative investment income of 10,888,387.92 yuan[58] - The company's other financial assets had an initial investment cost of 267,576,048.84 yuan, with a cumulative investment income of 562,691,563.37 yuan[58] - The company's financial derivatives had a cumulative fair value change of -27,649,894.23 yuan[58] - The company's entrusted wealth management products had a total amount of 132,500 million yuan, with an outstanding balance of 41,814.97 million yuan[60] - The company's forward foreign exchange contracts had an initial investment amount of 669,919.2 million yuan, with a fair value change of -5,180.51 million yuan[61] - The company's forward foreign exchange contracts had a final amount of 327,832.8 million yuan, accounting for 25.19% of the company's net assets at the end of the reporting period[61] - The company's actual loss from forward contracts and related foreign exchange transactions was 4,585.70 million yuan[61] - The company's financial derivatives are valued based on the market price of the USD/CNY spot rate at the end of each month[62] - The company's financial derivatives investment was approved by the board of directors on March 28, 2024, and by the shareholders' meeting on June 6, 2024[62] - Kanglong Chem (Ningbo) Technology Development Co., Ltd., a wholly-owned subsidiary, reported total assets of 2.297 billion yuan, net assets of 1.793 billion yuan, operating income of 871.86 million yuan, and net profit of 147.85 million yuan[66] Business Operations and Strategy - The company's CDMO business contributed $400 million, accounting for 33% of total revenue[2] - The company plans to expand its production capacity in the second half of 2024, with an investment of $200 million[4] - The number of active clients increased by 10% to 1,500, with 30% of revenue coming from new clients[2] - The company's gross margin remained stable at 35%, reflecting efficient cost management[2] - The company issued $300 million in zero-coupon convertible bonds due in 2026[7] - New orders signed in the first half of 2024 increased by over 15% year-over-year[22] - The company participated in 666 drug discovery projects in the first half of 2024, an increase of 16 projects year-over-year[27] - Laboratory services new orders increased by over 10% year-over-year, with biological sciences accounting for over 53% of laboratory services revenue[27] - CMC (small molecule CDMO) services new orders increased by over 25% year-over-year, with 78% of revenue coming from existing drug discovery service clients[28] - The company's laboratory services team consists of 9,377 employees, including nearly 6,000 laboratory chemistry researchers[28] - The company's CMC (small molecule CDMO) services team consists of 4,228 employees, with 695 drug molecules or intermediates involved in projects[29] - The company's clinical research services team consists of 3,899 employees, with a 96-bed early-stage clinical research center in Maryland, USA[31] - The number of ongoing clinical trial service projects reached 1,112, including 77 Phase III trials, 409 Phase I/II trials, and 626 other clinical trials[32] - The company provided efficacy determination and release services for 21 cell and gene therapy products from 17 clients, including 9 clinical-stage projects and 2 commercial projects[32] - The company's Carlsbad in vivo toxicology research center in California has been partially operational, supporting cell and gene therapy products, ophthalmic products, and medical devices[33] - The global biotech financing market showed signs of recovery, with increased funding for biotech companies, indicating a potential rebound in client demand[33] - The company's integrated platform offers end-to-end services from drug discovery to clinical development, with a strong presence in China, the US, and the UK[35] - The company's chemical technology platform covers the entire small molecule drug R&D process, from compound design to GMP-compliant commercial production[37] - The company's DMPK/ADME global service network includes advanced technologies like radioactive isotope analysis, enhancing its position as a leading integrated service provider[37] - Established a comprehensive drug discovery to clinical proof-of-concept integrated service platform, covering multiple disciplines such as drug molecule design, compound library synthesis, and clinical data statistics[38] - Built a domestic clinical research platform offering end-to-end services for Phase I-IV clinical development, enhancing competitiveness through internal growth and external acquisitions[38] - Developed a gene therapy "lab analysis-IND study-process development & production" integrated platform, including GLP/GCP/GMP-compliant facilities in the US and UK[40] - Operates 21 entities globally (11 overseas), leveraging international operations to provide customized services and solutions across key pharmaceutical regions[40] - Acquired advanced production equipment and leased a Singapore-based formulation factory, expanding global CDMO service capabilities[42] - Focused on innovation in chemical and biological technologies, including fluid chemistry, biocatalysis, and gene editing platforms[43] - Maintains a workforce of 18,241 R&D, production, and clinical service personnel across China, the UK, and the US as of June 30, 2024[44] - Strengthened international operations through strategic acquisitions, integrating top-tier talent and facilities into the integrated R&D service platform[41] - Collaborated with US-based clinical pharmacology teams to support domestic clients in filing IND applications and conducting first-in-human studies in the US[40] - Enhanced global service network by investing in PharmaGend and acquiring Strides Pharma Global's production assets in Singapore[42] - The company added over 360 new clients in the first half of 2024, with over 97% of revenue coming from repeat clients[46] - The company aims to strengthen its leadership in small molecule R&D services and expand into new drug fields such as oligonucleotides, peptides, antibodies, ADC, and cell and gene therapy products[69] - Kanglong Chem plans to enhance its CMC (small molecule CDMO) service competitiveness by integrating commercial capabilities in China, the UK, and the US, and improving resource utilization and production efficiency[69] - The company will focus on improving the integration of its clinical development platform, particularly enhancing collaboration between US and Chinese teams to support the global expansion of Chinese innovative drugs[70] - Kanglong Chem will continue to develop its large molecule and cell and gene therapy service platforms, expanding service content and increasing operational efficiency[70] - The company plans to strengthen talent acquisition and retention, particularly in drug R&D, and enhance internal training programs to support long-term sustainable development[71] - Kanglong Chem will further enhance the synergy of its integrated platform by improving management efficiency and reducing costs[71] - The company will intensify its business and market development efforts, particularly in overseas markets, by deepening customer relationships and expanding service offerings[72] - Kanglong Chem will prioritize production safety and intellectual property security, ensuring high-quality products and services while adhering to international quality standards[73] - The company plans to deepen its CRO+CDMO integrated platform and expand its customer base to strengthen its competitive position[79] - The company will invest heavily in new technologies and consider acquisitions to enhance its service capabilities[80] - Maintaining high service quality is crucial, as any failure could lead to client loss and reputational damage[80] Environmental, Social, and Governance (ESG) - The company's ESG initiatives reduced carbon emissions by 15% compared to the previous year[7] - The company's ESG rating was upgraded to AA, and it was included in the 2024 A-share listed companies ESG Excellence TOP100 and Corporate Governance (G) Dimension Best Practice TOP20[26] - The company adheres to environmental protection laws and regulations in China, the UK, and the US, including the Clean Water Act and Clean Air Act[96] - Completed environmental self-acceptance for the application of biological in vitro test models to study drug efficacy and druggability platform project on April 13, 2023[98] - Obtained the first pollutant discharge permit on October 14, 2019, with the current permit valid until October 13, 2027[98] - Completed environmental self-acceptance for the new drug R&D outsourcing service base expansion project in Tianjin in November 2022[99] - Received approval for hazardous waste transfer to Hebei Province for utilization on January 24, 2024, with approval number Jinkaihuan Guzhuan [2024]10[100] - Received approval for hazardous waste transfer to Shandong Province for utilization on March 14, 2024, with approval number Jinkaihuan Guzhuan [2024]30[100] - Reapplied and obtained approval for the pollutant discharge permit on June 6, 2024[100] - Approved for the environmental impact assessment of the Xi'an R&D Center (Phase II) project on December 30, 2015, with approval number Jingkaihuan Pifu [2015]235[101] - Obtained the pollutant discharge permit for Xi'an on December 14, 2020, valid until December 13, 2023[101] - Completed environmental self-acceptance for the new drug R&D outsourcing platform expansion project in Beijing on August 20, 2020[97] - Approved for the environmental impact assessment of the new drug R&D outsourcing platform in vitro pharmacokinetics project on November 20, 2020, with approval number Jinghuan Shenzi [2020]0093[97] - The company completed the environmental protection acceptance monitoring report for the 120 tons/day laboratory wastewater treatment project at Kanglong Huacheng (Xi'an) New Drug Technology Co., Ltd., which was approved by the expert group[102] - The company obtained a pollutant discharge permit for Kanglong Huacheng (Xi'an) New Drug Technology Co., Ltd., valid until December 13, 2028[102] - The company completed the environmental impact assessment and acceptance monitoring reports for multiple projects in the Hangzhou Bay Life Science Park, including the bio-pharmaceutical R&D base and animal laboratory public service platform[103] - The company obtained environmental impact assessment approvals for the second phase of the Hangzhou Bay Life Science Industrial Park bio-pharmaceutical R&D service base project[103] - The company completed the environmental impact assessment and acceptance monitoring reports for the annual production of 47 tons and 25 tons of pharmaceutical intermediates at Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd.[104] - The company obtained a pollutant discharge permit for Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd., valid until October 10, 2026[104] - The company completed the environmental protection facility acceptance report for the annual production of 25 tons of pharmaceutical intermediates at Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd.[105] - The company obtained environmental impact assessment approvals for the new drug development technology service platform project at Kanglong Huacheng (Beijing) Technology Development Co., Ltd.[106] - The company completed the environmental impact assessment and adjustment report for the innovation center bio-pharmaceutical innovation platform project at Kanglong Huacheng (Ningbo) Bio-pharmaceutical Co., Ltd.[106] - The company reported the discharge of major pollutants, including CODcr, PH, NH3-N, and SS, at Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd., with no超标排放情况[107] - Average concentration of VOCs emissions is 1.435 mg/m³, with a total emission of 11.28 tons[108] - Average concentration of nitrogen oxides emissions is 17 mg/m³, with a total emission of 0.2737 tons[108] - Total emission of waste organic solvents is 2094.547 tons[108] - Total emission of contaminated waste packaging is 606.45 tons[108] - Total emission of waste activated carbon is 14.836 tons[108] - Total emission of waste silica gel is 64.676 tons[108] - Total emission of laboratory waste is 20.475 tons[108] - Total emission of waste oil is 0 tons[109] - Total emission of expired and invalid drugs is 0 tons[109] - Total emission of COD

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 就2024年第一次臨時股東大會 暫停辦理股份過戶登記手續 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會謹此宣佈，為釐定有 權出席謹定於2024年9月13日（星期五）下午2時30分舉行的2024年第一次臨時股 東大會（「臨時股東大會」），並於會上投票的本公司H股（「H股」）股東名單，本公 司將於2024年9月10日（星期二）至2024年9月13日（星期五）期間（包括首尾兩日） 暫停辦理H股股份過戶登記手續，該期間將不會辦理H股股份過戶登記手續。於 2024年9月10日（星期二）名列本公司股東名冊的H股股東將有權出席臨時股東大 會並於會上投票。 為符合資格出席臨時股東大會並於會上投票，所有H股過戶文件連同有 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-052 康龙化成（北京）新药技术股份有限公司 关于参与私募股权投资基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易背景概述 为充分运用专业投资基金在行业内项目收集、研判的能力，提高公司投资能 力，康龙化成（北京）新药技术股份有限公司（以下简称"公司"或"康龙化成"） 以自有资金认缴出资人民币 10,000 万元作为有限合伙人参与投资无锡阿斯利康 中金创业投资合伙企业（有限合伙）（以下简称"阿斯利康基金" 或"合伙企 业 " ） 。 具 体 内 容 详 见 2020 年 10 月 20 日 公 司 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于参与投资无锡阿斯利康中金创业投资 合伙企业（有限合伙）的公告》（公告编号：2020-087）。 2021 年 1 月 28 日，阿斯利康基金已根据《证券投资基金法》和《私募投资 基金监督管理暂行办法》等法律法规的要求在中国证券投资基金业协会完成基金 的备案手续，并取得《私募投资基金备案证明》。具 ...